• bladder pain syndrome
  • AQXP ), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today issued the following statements following the U.S. Food and Drug Administration (FDA) Bone, Reproductive, and Urologic Drugs Advisory Committee meeting on interstitial cystitis/bladder pain syndrome (IC/BPS). (globenewswire.com)